Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults

(2018) Alvaro Cobo-Calvo et al.   NEUROLOGY

Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis

(2018) Jiraporn Jitprapaikulsan et al.   OPHTHALMOLOGY

Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis

(2018) Jiraporn Jitprapaikulsan et al.   JAMA Neurology

Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination

(2017) Patrick Peschl et al.   Journal of Neuroinflammation

Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial

(2017) Zahra Nikoo et al.   JOURNAL OF NEUROLOGY

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response

(2017) Jan-Patrick Stellmann et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea

(2017) Jin Myoung Seok et al.   Multiple Sclerosis Journal

Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea

(2017) Jin Myoung Seok et al.   Multiple Sclerosis Journal

Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity

(2017) Youming Long et al.   Frontiers in Neurology

Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum

(2016) Eoin P. Flanagan et al.   ANNALS OF NEUROLOGY

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome

(2016) Sven Jarius et al.   Journal of Neuroinflammation

Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints

(2015) In Hye Jeong et al.   Multiple Sclerosis Journal

Challenges and opportunities in designing clinical trials for neuromyelitis optica

(2015) B. G. Weinshenker et al.   NEUROLOGY

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

(2015) Dean M. Wingerchuk et al.   NEUROLOGY

Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints

(2015) In Hye Jeong et al.   Multiple Sclerosis Journal

Placebo controlled trials in neuromyelitis optica are needed and ethical

(2015) Bruce A.C. Cree   Multiple Sclerosis and Related Disorders

Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies

(2014) Joanna Kitley et al.   JAMA Neurology

Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica

(2014) Maureen A. Mealy et al.   JAMA Neurology

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials

(2013) J. Kitley et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset

(2013) N Collongues et al.   Multiple Sclerosis Journal

Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica

(2013) Y. Jiao et al.   NEUROLOGY

Factors Associated With the Time to Next Attack in Neuromyelitis Optica: Accelerated Failure Time Models With Random Effects

(2013) Sung-Min Kim et al.   PLoS One

Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica

(2012) Ingo Kleiter   ARCHIVES OF NEUROLOGY

Effects of Age and Sex on Aquaporin-4 Autoimmunity

(2012) Amy M. L. Quek et al.   ARCHIVES OF NEUROLOGY

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan

(2012) Joanna Kitley et al.   BRAIN

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy

(2011) MH Barnett et al.   Multiple Sclerosis Journal

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder

(2011) Ju-Hong Min et al.   Multiple Sclerosis Journal

Neuromyelitis optica in France: A multicenter study of 125 patients

(2010) N. Collongues et al.   NEUROLOGY

IFN -1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum

(2010) J. Shimizu et al.   NEUROLOGY

Long-term follow-up of neuromyelitis optica with a pediatric onset

(2010) N. Collongues et al.   NEUROLOGY

Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis

(2009) A. Uzawa et al.   EUROPEAN JOURNAL OF NEUROLOGY